close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

46.30 +0.37 (+0.79%)
Streaming Delayed Price Updated: 3:00 PM EST, Nov 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
82 83 Next >
News headline image
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
News headline image
Why US Drug Giant Bristol Myers Squibb Stock Trading Up On Monday ↗
Bristol Myers Squibb's KRYSTAL-12 study reveals Krazati's significant benefits over chemotherapy for KRASG12C-mutated NSCLC, improving progression-free survival and response rates. 
Via Benzinga
News headline image
6% Yield Bristol Myers Squibb Value Trap Or Long-Term Opportunity? ↗
BMY is offering a 6% yield and trading for less than 9 times earnings. 
Via Talk Markets
News headline image
Bristol-Myers Squibb's Options: A Look at What the Big Money is Thinking ↗
 
Via Benzinga
News headline image
(BMY) - Analyzing Bristol-Myers Squibb's Short Interest ↗
 
Via Benzinga
News headline image
Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
News headline image
This Unpopular Dividend Stock Is a Buy ↗
This top pharma stock has fallen too far. 
Via The Motley Fool
News headline image
Spotlight on Bristol-Myers Squibb: Analyzing the Surge in Options Activity ↗
 
Via Benzinga
News headline image
2 No-Brainer Dividend Stocks You Can Buy With $100 in June ↗
This pair of high-yield dividend payers offer yields near 6% and a chance for steady payout raises in the years to come. 
Via The Motley Fool
News headline image
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
News headline image
FDA Expands Approval For Bristol Myers Squibb's Breyanzi, Making CAR T Cell Therapy Available For Broadest Range Of B-Cell Malignancies ↗
FDA approves Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) for relapsed or refractory mantle cell lymphoma, marking its fourth non-Hodgkin lymphoma subtype indication. 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
From Bristol Myers Squibb
Via Business Wire
News headline image
7 Underappreciated Stocks With 25% Return Potential in 2024 ↗
Each of these underappreciated stocks is expected to provide 25%+ returns this year, which is reason enough to pay attention. 
Via InvestorPlace
News headline image
Are Boomers Crashing The Economy Or Saving It? Why Investors Are Perplexed And What You Can Do To Prepare ↗
Mass retirement of boomers could have major economic impact. Experts anticipate both risks and opportunities from the largest wealth transfer in history. 
Via Benzinga
Topics Economy Retirement
News headline image
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
From Bristol Myers Squibb
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields ↗
 
Via Benzinga
News headline image
3 Blue-Chip Stocks to Buy at 52-Week Lows in May ↗
These three blue-chip stocks at a 52-week low could provide investors with a good opportunity to open a new position or double an old one. 
Via InvestorPlace
News headline image
S&P 500 Earnings Dashboard 24Q1 - Saturday, May 25 ↗
Of the 480 companies in the S&P 500 that have reported earnings to date for 24Q1, 77.9% reported above analyst expectations. This compares to a long-term average of 66%. 
Via Talk Markets
Topics Stocks
News headline image
Retail Earnings & Consumer Spending: A Closer Look ↗
The U.S. economy is chugging along, with growth moderately decelerating under the Fed’s tight monetary policy. Most of the Q1 earnings season is behind us, with results from 481 S&P 500 companies... 
Via Talk Markets
Topics Economy Stocks
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday? ↗
Verastem Oncology reports promising initial results from the RAMP 205 trial with an 83% ORR for avutometinib and defactinib in metastatic pancreatic cancer. FDA submission for recurrent KRAS mutant... 
Via Benzinga
News headline image
Bonds Break Down And Send Everyone To Cash ↗
This situation is where the danger, the opportunity, and the action are right now. 
Via Talk Markets
News headline image
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
From Bristol Myers Squibb
Via Business Wire
News headline image
Hawaii Court Rules Against Bristol Myers, Sanofi In Blood Clot Drug Case, Increases Liability To $916M ↗
A Hawaii judge has ordered Bristol Myers Squibb and Sanofi to pay $916 million for not warning non-white patients about the health risks of their blood thinner Plavix. The ruling follows a previous... 
Via Benzinga
News headline image
Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
From Bristol Myers Squibb
Via Business Wire
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
82 83 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today